Treatment of clozapine-associated weight gain: A systematic review

European Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2015, Pages 389-401

  Whitney, Z ^a   Procyshyn, R M ^a,b   Fredrikson, D H ^a   Barr, A M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Adjunct medication; Antipsychotic; Clozapine; Obesity; Psychosis; Weight gain

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CLOZAPINE; FLUVOXAMINE; LITHIUM; METFORMIN; MODAFINIL; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZIPRASIDONE; NEUROLEPTIC AGENT;

COGNITIVE THERAPY; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; LIFESTYLE MODIFICATION; MULTICENTER STUDY (TOPIC); OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG EFFECTS; SCHIZOPHRENIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84925497728     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1807-1     Document Type: Review

References (70)

1. Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2(5):e141
2. Koster LS, Carbon M, Correll CU (2014) Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs 19(4):1 - 21
3. Conley RR, Kelly DL (2001) Management of treatment resistance in schizophrenia. Biol Psychiatry 50(11):898-911
4. Sinclair D, Adams CE (2014) Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatr 14(1):253
5. Meltzer HY (2012) Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6(3):134-144
6. Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM (2009) A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci 34(6):433-442
7. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085-1097
8. McIlwain ME, Harrison J, Wheeler AJ, Russell BR (2011) Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 7:135-149
9. Frogley C, Taylor D, Dickens G, Picchioni M (2012) A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 15(9):1351-1371
10. Mamo DC (2007) Managing suicidality in schizophrenia. Can J Psychiatry 52(6 Suppl 1):59S-70S
11. Shen WW (1999) A history of antipsychotic drug development. Compr Psychiatry 40(6):407-414
12. Ashby CR Jr, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24(4):349-394
13. Divac N, Prostran M, Jakovcevski I, Cerovac N (2014) Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014:656370
14. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC (2012) Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135(2):113-122
15. Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J (2012) Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140(1-3):204-213
16. Baptista T (2014) A fatal case of ischemic colitis during clozapine administration. Rev Bras Psiquiatr 36(4):358
17. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1-93
18. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80(1):19-32
19. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, Barr AM (2010) A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 34(6):945-954
20. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31(10):484-497
21. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125(1):169-179
22. Roerig JL, Steffen KJ, Mitchell JE (2011) Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 25(12):1035-1059
23. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149(1):68-72
24. Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC (2010) Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry 22(1):33-42
25. Meltzer HY, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59(1):19-27
26. Citrome L, Vreeland B (2008) Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 120(2):18-33
27. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61(8):1356-1370
28. Brown S (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171:502-508
29. DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26(5):649-666
30. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE, Goff DC (2006) An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113(2):142-147
31. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115-1125
32. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31-41
33. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC (2009) Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 24(3):225-232
34. Ryan DH (2000) Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine 13(2):193-199
35. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC (2007) A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115(2):101-105
36. Blanck HM, Khan LK, Serdula MK (2001) Use of nonprescription weight loss products: results from a multistate survey. JAMA 286(8):930-935
37. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE (2002) Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 63(4):345-348
38. Vaughan B, Kratochvil CJ (2012) Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 21(4):941-955
39. Wernicke JF, Kratochvil CJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63(Suppl 12):50-55
40. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW (2011) Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5(1):17-25
41. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S (2011) Topiramate-induced weight loss: a review. Epilepsy Res 95(3):189-199
42. Luykx JJ, Carpay JA (2010) Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf 9(4):623-631
43. Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, Talaei M (2009) Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 23(2):157-162
44. Hahn MK, Remington G, Bois D, Cohn T (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30(6):706-710
45. Salzman C (2003) New uses for lithium and anticonvulsants. Harv Rev Psychiatr 11(5):230-244
46. Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M, Rosa AR, Scott J, Vieta E (2008) Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 118(1):4-18
47. Repantis D, Schlattmann P, Laisney O, Heuser I (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62(3):187-206
48. Kumar R (2008) Approved and investigational uses of modafinil: an evidence-based review. Drugs 68(13):1803-1839
49. Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, Fan X, Cather C, Goff DC (2011) Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res 130(1-3):53-56
50. Dell'Osso B, Allen A, Hollander E (2005) Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 6(15):2727-2740
51. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65(6):766-771
52. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32(4):148-153
53. Scarpello JH, Howlett HC (2008) Metformin therapy and clinical uses. Diab Vasc Dis Res 5(3):157-167
54. Nasri H, Rafieian-Kopaei M (2014) Metformin: current knowledge. J Res Med Sci 19(7):658-664
55. Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, Valbuena D, Fernandez I, de Baptista EA, Baptista T (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113(1):19-26
56. Chen CH, Huang MC, Kao CF, Lin SK, Kuo PH, Chiu CC, Lu ML (2013) Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 74(5):e424-e430
57. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281(3):235-242
58. Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, Eronen M, Rasanen P (2008) Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):706-711
59. Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, Terevnikov V, Stenberg JH, Eronen M, Joffe G (2011) Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 72(3):326-330
60. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193(2):101-107
61. Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP (2006) Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 40(9):810-814
62. FAO/WHO/UNU (1985) Energy and protein requirements: report of a joint FAO/WHO/UNU expert consultation committee. World Health Organization, Geneva, (No. 724)
63. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD (2007) Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 58(4):544-550
64. Faulkner G, Cohn T, Remington G (2007) Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 1, CD005148
65. Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477-495
66. Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35(7):1520-1530
67. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566-573
68. Boyda HN, Procyshyn RM, Tse L, Xu J, Jin CH, Wong D, Pang CC, Honer WG, Barr AM (2013) Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 21(2):164-171
69. Boyda HN, Procyshyn RM, Asiri Y, Wu C, Wang CK, Lo R, Pang CC, Honer WG, Barr AM (2014) Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 48:170-176
70. Boyda HN, Procyshyn RM, Tse L, Hawkes E, Jin CH, Pang CC, Honer WG, Barr AM (2012) Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 37(6):407-415